RESUMO
In dye-sensitized solar cells (DSSCs), a significant dye-regeneration force (ΔG(reg)(0)≥0.5â eV) is usually required for effective dye regeneration, which results in a major energy loss and limits the energy-conversion efficiency of state-of-art DSSCs. We demonstrate that when dye molecules and redox couples that possess similar conjugated ligands are used, efficient dye regeneration occurs with zero or close-to-zero driving force. By using Ru(dcbpy)(bpy)2(2+) as the dye and Ru(bpy)2(MeIm)2(3+//2+) as the redox couple, a short-circuit current (J(sc)) of 4â mA cm(-2) and an open-circuit voltage (V(oc)) of 0.9â V were obtained with a ΔG(reg)(0) of 0.07â eV. The same was observed for the N3 dye and Ru(bpy)2(SCN)2(1+/0) (ΔG(reg)(0)=0.0â eV), which produced an J(sc) of 2.5â mA cm(-2) and V(oc) of 0.6â V. Charge recombination occurs at pinholes, limiting the performance of the cells. This proof-of-concept study demonstrates that high V(oc) values can be attained by significantly curtailing the dye-regeneration force.
RESUMO
The global scientific response to COVID 19 highlighted the urgent need for increased throughput and capacity in bioanalytical laboratories, especially for the precise quantification of proteins that pertain to health and disease. Acoustic ejection mass spectrometry (AEMS) represents a much-needed paradigm shift for ultra-fast biomarker screening. Here, a quantitative AEMS assays is presented, employing peptide immunocapture to enrich (i) 10 acute phase response (APR) protein markers from plasma, and (ii) SARS-CoV-2 NCAP peptides from nasopharyngeal swabs. The APR proteins were quantified in 267 plasma samples, in triplicate in 4.8 h, with %CV from 4.2% to 10.5%. SARS-CoV-2 peptides were quantified in triplicate from 145 viral swabs in 10 min. This assay represents a 15-fold speed improvement over LC-MS, with instrument stability demonstrated across 10,000 peptide measurements. The combination of speed from AEMS and selectivity from peptide immunocapture enables ultra-high throughput, reproducible quantitative biomarker screening in very large cohorts.